Skip to content
Peptigraph home

Bimagrumab Phase 2 trial (NCT03005288)

A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
78
actual
Start
1 Feb 2017 (actual)
Primary completion
21 Mar 2019 (actual)
Sponsor
Novartis Pharmaceuticals
Design

Arms and doses

NCT03005288 study arms
ArmTypeInterventionsDescription
BYM338 10 mg/kgExperimentalDrug: BYM338 10 mg/kgBimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)
PlaceboPlacebo comparatorOther: PlaceboPlacebo, every 4 weeks until week 44 (12 doses)
Endpoints

Primary endpoint

NCT03005288 primary outcomes
MeasureTime frame
Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48Baseline, Week 48
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT03005288 secondary outcomes
MeasureTime frame
Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 24Baseline, Week 24
Change From Baseline in HbA1c at Week 24 and 48Baseline, Week 24, Week 48
The Trough Observed Analyte Concentration (Ctrough) of Repeat Doses of BYM338 10 mg/kg on Day 84, 168, 252, 308 and 336Day 84, 252, 336 at pre-dose only. Day 168, 308 at pre-dose and 45 mins post-dose
Maximum Observed Serum Concentration(Cmax) Derived on Day 1, 168 and 308Day 1, 168, 308 at pre-dose and 45 mins post-dose
Time to Reach the Maximum Concentration After Drug Administration (Tmax) Derived on Day 168 and 308Day 1, 168, 308 at pre-dose and 45 mins post-dose
Change From Baseline in Body Mass Index (BMI)Baseline, Week 24, Week 48
Change From Baseline in WeightBaseline, Week 24, Week 48
Change From Baseline in Lean Body Mass (LBM) Measured by DXABaseline, Week 24, Week 48
Change From Baseline in Waist CircumferenceBaseline, Week 24, Week 52
Change From Baseline in Waist to Hip RatioBaseline, Week 24, Week 52
Change From Baseline in Insulin Resistance (HOMA2-IR)Baseline. Week 12, Week 36
Immunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial392 days
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT03005288.

What the registry posted for the bimagrumab fat-mass outcome

The posted primary outcome is the change from baseline in total body fat mass by DXA at week 48.[1]

Outcome group OG000 is labelled BYM338 10 mg/kg, which is the code name for bimagrumab.[1]

The posted least-squares mean change in fat mass was -7.49 kg in the first group, with bounds of -8.33 to -6.64, and -0.18 kg in the second, with bounds of -0.99 to 0.63.[1]

The posted net mean difference was -7.31, with an 80% two-sided interval of -8.48 to -6.14.[1]

Sources

  1. 1A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.